These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15273100)

  • 1. Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
    Hickman D; Vasavanonda S; Nequist G; Colletti L; Kati WM; Bertz R; Hsu A; Kempf DJ
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2911-7. PubMed ID: 15273100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection.
    Estrela RC; Ribeiro FS; Seixas BV; Suarez-Kurtz G
    Rapid Commun Mass Spectrom; 2008; 22(5):657-64. PubMed ID: 18257112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
    Castagna A; Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Hoetelmans R; Nauwelaers D; Lazzarin A
    Antivir Ther; 2004 Aug; 9(4):537-43. PubMed ID: 15456085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
    González de Requena D; Gallego O; Valer L; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):275-8. PubMed ID: 15117450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.
    Azoulay S; Nevers MC; Créminon C; Heripret L; Garraffo R; Durant J; Dellamonica P; Grassi J; Guedj R; Duval D
    J Immunol Methods; 2004 Dec; 295(1-2):37-48. PubMed ID: 15627609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
    Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF
    Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced lopinavir exposure during pregnancy.
    Stek AM; Mirochnick M; Capparelli E; Best BM; Hu C; Burchett SK; Elgie C; Holland DT; Smith E; Tuomala R; Cotter A; Read JS
    AIDS; 2006 Oct; 20(15):1931-9. PubMed ID: 16988514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects.
    Yadav M; Rao R; Kurani H; Singhal P; Goswami S; Shrivastav PS
    J Pharm Biomed Anal; 2009 May; 49(4):1115-22. PubMed ID: 19282124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
    Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
    Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
    McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.